Expand CMPX Menu
CMPX MENU

CMPX Latest Press Releases

-- August 6, 2026 --

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- July 17, 2026 --

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 Globe Newswire 10:42 AM

-- June 30, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 9:00 AM

-- June 12, 2026 --

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell Globe Newswire 8:10 AM

-- May 28, 2026 --

Compass Therapeutics to Participate in Upcoming June Investor Events Globe Newswire 7:30 AM

-- May 21, 2026 --

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting Globe Newswire 5:00 PM

-- May 19, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX Globe Newswire 6:09 PM

-- May 14, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PRNewswire 11:01 PM

-- May 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX Globe Newswire 4:57 PM
Compass Therapeutics to Participate in Upcoming May Investor Events Globe Newswire 7:30 AM

-- May 5, 2026 --

Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update Globe Newswire 7:30 AM

-- April 30, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Compass Therapeutics, Inc. - CMPX PRNewswire 7:42 PM

-- April 27, 2026 --

Compass Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Globe Newswire 1:00 PM
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Globe Newswire 7:30 AM

-- April 24, 2026 --

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer Globe Newswire 4:00 PM
Market Data Delayed 15 Minutes